IMR Press / EJGO / Volume 23 / Issue 2 / pii/2002128

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Original Research

Tibolone versus 17β-estradiol/norethisterone: Effects on the proliferation of human breast cancer cells

Show Less
1 Section of Endocrinology and Menopause, Department of Obstetrics and Gynecology, University of Tuebingen, Tuebingen (Germany)
Eur. J. Gynaecol. Oncol. 2002, 23(2), 127–130;
Published: 10 April 2002

Tibolone is a synthetic progestin with estrogenic and progestogenic properties, widely used for alleviation of menopausal syn­dromes and for osteoporosis prophylaxis in postmenopausal women. Since only little data are available on tibolone and breast cancer risk the present study investigates the effect of tibolone on the growth of the human breast cancer cell line, MCF-7. Tibolone is cli­nically comparable to an estradiol/norethisterone combination, therefore we included this hormone combination in our experiments. Tibolone was examined alone and in the presence of 0.l nM estradiol in the concentration range from 0.001 µM to 1 µM. Norethi­sterone was studied using the same concentration range in combination with 0.1 nM estradiol. Tibolone led to significant cell growth in the concentration range of 0.01 to 1 µM and was able to significantly stimulate estra­diol-induced proliferation at the concentrations 0.01 and 0.1 µM. In contrast, the estradiol/norethisterone combination elicited signi­ficant inhibition of cell growth at the concentrations 0.001 and 0.01 µM. These data suggest that tibolone does have tumor cell-growth promoting effects in vitro whereas the estradiol/norethisterone com­bination partially inhibits cell growth. Therefore no differences in risk profile are to be expected between conventional hormone substitution using estradiol and norethisterone acetate and tibolone. Drawing a clinical consequence from our experiments would result in not recommending the use of tibolone in postmenopausal women at high risk for breast cancer development until long­term controlled clinical studies have been performed on the effect of tibolone administration and breast cancer risk.

Breast cancer cell growth
Back to top